Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine

Clinical trial NCT06821100 · RECRUITING

Trial details

NCT number: NCT06821100
Sponsor: The Methodist Hospital Research Institute
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Vaccine Response COVID-19 Vaccine Immune Response to Covid 19 Vaccination

Start date: 2024-12-02
Primary completion: 2026-12-01
Enrollment: 75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.